Cancer Clinical Research Unit Trials

Click on trial for description and contact information.

 

Minority-Based Community Clinical Oncology Program trials.

Advanced Solid Malignancies

• Study of XL184 in Adults with Advanced Solid Tumors 
   
• Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors or Lymphoma
   

Breast Cancer

• Study of XL184 in Adults with Advanced Solid Tumors 
   

Blood Cancers 

• A Phase 1/1b Study of TRU-016 in Patients With Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin’s Lymphoma
   
• Dose Finding Study of Panobinostat Given in Combination With 5-Azacitidine in Patients With MDS, CMML or AML
   
• Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors or Lymphoma 
     
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (PANORAMA II)  
• Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (This study is ongoing but currently not recruiting patients.)
   
• A Phase 2, multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib
   
• A single arm, phase II, open-label study to determine the efficacy of 100mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease
   

Chest and Lung Cancer

• Study of XL184 in Adults with Advanced Solid Tumors 
   

Gastrointestinal Cancer

• Study of XL184 in Adults with Advanced Solid Tumors 
   

Genitourinary / Prostate Cancer

• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD3)
   
• Study of XL184 in Adults with Advanced Solid Tumors 
    
    
•  Phase 3, Randomized, Double-Blind Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer. 
   

Gynecologic Cancer

• Study of XL184 in Adults with Advanced Solid Tumors 
    
   
• Study of XL147 in Advanced or Recurrent Endometrial Cancer
   
•  

Skin Cancer

• Study of XL184 in Adults with Advanced Solid Tumors
   
• A Phase I/II, open-label, dose escalation trial to evaluate the safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or Metastatic Melanoma
   

 

[Back to Top]